OATD-01 (OncoArendi Therapeutics oral, first-in-class CHIT1/AMCase chitinase inhibitor clinical candidate)
< 1 minute read
Sep. 18, 2021
OATD-01: An Oral, First-In-Class CHIT1/AMCase Chitinase Inhibitor
OATD-01
oral, first-in-class CHIT1/AMCase chitinase inh. for sarcoidosis/lung fibrosis, Ph. Ib complete from opt. of literature molecule J. Med. Chem., Oct. 20, 2020 OncoArendi Therapeutics SA, Warsaw, PL
Loading...
